Comparative Effectiveness of Antiviral Agents and Monoclonal Antibodies for Early SARS-CoV-2 Therapy in Immunocompromised Patients: A Multicenter Retrospective Cohort Study (March 2021–March 2022)

Comparative Effectiveness of Antiviral Agents and Monoclonal Antibodies for Early SARS-CoV-2 Therapy in Immunocompromised Patients: A Multicenter Retrospective Cohort Study (March 2021–March 2022)

Immunocompromised (IC) patients continue to be at risk of severe COVID-19 despite vaccination and anti-SARS-CoV-2 therapies. The comparative effectiveness of antiviral agents (AVAs) and monoclonal antibodies (MoAbs) as early treatment of SARS-CoV-2 in IC patients is described in this work. This retr...

Full description

Saved in:
Bibliographic Details
Main Authors: Serena Vita, Gaetano Maffongelli, Tommaso Ascoli Bartoli, Domenico Benvenuto, Raffaella Marocco, Silvia Rosati, Valentina Mazzotta, Cosmo Del Borgo, Ilaria Mastrorosa, Patrizia De Marco, Alessandra D’Abramo, Fabrizio Maggi, Andrea Antinori, Miriam Lichtner, Emanuele Nicastri, COVID Group
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Microorganisms
Subjects:
SARS-CoV-2
COVID-19
immunocompromised patients
antiviral agents
monoclonal antibodies
Online Access:https://www.mdpi.com/2076-2607/13/5/1076
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-2607/13/5/1076

Similar Items